Drug intelligence / Profile preview

BDX100

Development stage: Preclinical
Lead developer: Biodextris
Modality: Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
Administration: Intranasal

Overview

BDX100 is a proprietary intranasal mucosal adjuvant developed by Biodextris. It is designed to enhance the immunogenicity of intranasally delivered vaccine antigens, particularly by promoting mucosal IgA and systemic IgG responses. In March 2021, Biodextris entered into a material transfer agreement with Oragenics to evaluate BDX100, alongside BDX300 and BDX301, as part of Oragenics' Terra CoV-2 vaccine program for COVID-19. The adjuvant technology is intended to provide a needle-free vaccination route that can potentially block viral transmission at the point of entry by stimulating immunity directly at the respiratory mucosa.

Targets

TLR4 (Toll-like receptor 4)TLR2 (Toll-like Receptor 2)

Beyond the preview

Go deeper on BDX100.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BDX100.

Explore the full profile